Dimensional Fund Advisors LP Raises Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,035,070 shares of the specialty pharmaceutical company's stock after purchasing an additional 320,724 shares during the quarter. Dimensional Fund Advisors LP owned about 3.37% of Jazz Pharmaceuticals worth $250,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Forum Financial Management LP bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $245,000. Freedom Investment Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 13.0% in the 4th quarter. Freedom Investment Management Inc. now owns 2,406 shares of the specialty pharmaceutical company's stock valued at $296,000 after buying an additional 276 shares during the period. GeoWealth Management LLC increased its position in Jazz Pharmaceuticals by 184.3% in the 4th quarter. GeoWealth Management LLC now owns 762 shares of the specialty pharmaceutical company's stock valued at $94,000 after buying an additional 494 shares in the last quarter. Commerce Bank acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $256,000. Finally, Dean Investment Associates LLC boosted its holdings in Jazz Pharmaceuticals by 15.2% in the fourth quarter. Dean Investment Associates LLC now owns 28,451 shares of the specialty pharmaceutical company's stock worth $3,504,000 after acquiring an additional 3,753 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $1.82 during mid-day trading on Friday, reaching $110.80. 896,340 shares of the company's stock were exchanged, compared to its average volume of 795,740. The business's fifty day simple moving average is $125.13 and its 200 day simple moving average is $122.18. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The firm has a market capitalization of $6.73 billion, a PE ratio of 15.61, a P/E/G ratio of 1.04 and a beta of 0.42.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent research reports. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. HC Wainwright upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Barclays reiterated an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.